Skip to main content
Top
Published in: Clinical Rheumatology 5/2005

01-10-2005 | Original Article

Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus

Authors: Yasuhiro Shimojima, Masayuki Matsuda, Takahisa Gono, Wataru Ishii, Shu-ichi Ikeda

Published in: Clinical Rheumatology | Issue 5/2005

Login to get access

Abstract

Neuropsychiatric symptoms are often seen in patients with systemic lupus erythematosus (SLE). To investigate the relationship between involvement of the nervous system and clinical factors, including autoantibodies and the activity of SLE, we retrospectively reviewed 25 patients with neuropsychiatric SLE (NPSLE, mean age: 35.2±12.2 years). As controls 37 SLE patients without neuropsychiatric manifestations (mean age: 31.8±15.8 years) were employed in this study. At the onset no significant differences were seen in any clinical factors between the patients and the controls except for serum antinuclear antibodies. In relapse, the patients with NPSLE showed significantly lower levels of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores without neuropsychiatric evaluation (p<0.0001), erythrocyte sedimentation rate (ESR, p<0.005), and antinuclear and anti-double-stranded DNA antibodies (p<0.005) and higher WBC values (p<0.05) than at the onset. Also in the patients with relapsing NPSLE similar significant differences were seen in these parameters between onset and relapse (p<0.005). Despite a lack of significant differences, the cerebrospinal fluid showed lower values in cell counts, total protein, and IgG in relapse than at onset. These results suggest that there are no clinical factors that predict the development of NPSLE and that relapse can occur with low disease activity in the nervous system even with an inactive state of other organ involvement. Since NPSLE may suddenly relapse with a slight change in common disease activation markers, including inflammatory reactions, autoantibodies, and complements in serum and CSF findings, adequate corticosteroid and/or immunosuppressive agents should be given at the onset and gradually be tapered after recovery, while looking out for recurrence.
Literature
1.
go back to reference Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500 Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500
2.
go back to reference Hanly JG (2001) Neuropsychiatric lupus. Curr Rheumatol Rep 3:205–212 Hanly JG (2001) Neuropsychiatric lupus. Curr Rheumatol Rep 3:205–212
3.
go back to reference ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608 ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608
4.
go back to reference Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B (1992) Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 19:562–567 Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B (1992) Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 19:562–567
5.
go back to reference Jennekens FG, Kater L (2002) The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:619–630 Jennekens FG, Kater L (2002) The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:619–630
6.
go back to reference Hirohata S, Miyamoto T (1990) Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 33:644–649 Hirohata S, Miyamoto T (1990) Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 33:644–649
7.
go back to reference Hirohata S, Kosaka M (1994) Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus. Lancet 343:796 Hirohata S, Kosaka M (1994) Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus. Lancet 343:796
8.
go back to reference Swaak AJ, Huysen V, Nossent JC, Smeenk RJ (1990) Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin Rheumatol 9:82–94 Swaak AJ, Huysen V, Nossent JC, Smeenk RJ (1990) Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin Rheumatol 9:82–94
9.
go back to reference Silva LM, Garcia AB, Donadi EA (2002) Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249:1048–1054 Silva LM, Garcia AB, Donadi EA (2002) Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249:1048–1054
10.
go back to reference Isshi K, Hirohata S (1998) Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 41:1819–1827 Isshi K, Hirohata S (1998) Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 41:1819–1827
11.
go back to reference Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG et al (2002) Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 41:1357–1366 Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG et al (2002) Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 41:1357–1366
12.
go back to reference Yoshio T, Masuyama J, Kano S (1996) Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol 23:1311–1312 Yoshio T, Masuyama J, Kano S (1996) Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol 23:1311–1312
13.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed
14.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725 Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
15.
go back to reference Finn R, de M Rudolf N (1978) The electroencephalogram in systemic lupus erythematosus. Lancet 1:1255 Finn R, de M Rudolf N (1978) The electroencephalogram in systemic lupus erythematosus. Lancet 1:1255
16.
go back to reference Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H (1994) Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J Rheumatol 21:87–90 Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H (1994) Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J Rheumatol 21:87–90
17.
go back to reference Sibbitt WL Jr, Schmidt PJ, Hart BL, Brooks WM (2003) Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 30:1983–1989 Sibbitt WL Jr, Schmidt PJ, Hart BL, Brooks WM (2003) Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 30:1983–1989
18.
go back to reference Small P, Mass MF, Kohler PF, Harbeck RJ (1977) Central nervous system involvement in SLE. Diagnostic profile and clinical features. Arthritis Rheum 20:869–878 Small P, Mass MF, Kohler PF, Harbeck RJ (1977) Central nervous system involvement in SLE. Diagnostic profile and clinical features. Arthritis Rheum 20:869–878
19.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMed
20.
go back to reference Hirohata S, Hirose S, Miyamoto T (1985) Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Arch Intern Med 145:1843–1846 Hirohata S, Hirose S, Miyamoto T (1985) Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Arch Intern Med 145:1843–1846
21.
go back to reference Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG (1995) Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 98:32–41CrossRefPubMed Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG (1995) Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 98:32–41CrossRefPubMed
22.
go back to reference Hanly JG, Walsh NM, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741 Hanly JG, Walsh NM, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741
23.
go back to reference Devinsky O, Petito CK, Alonso DR (1988) Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 23:380–384 Devinsky O, Petito CK, Alonso DR (1988) Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 23:380–384
24.
go back to reference Zvaifler NJ, Bluestein HG (1982) The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 25:862–866 Zvaifler NJ, Bluestein HG (1982) The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 25:862–866
25.
go back to reference Ellis SG, Verity MA (1971) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8:212–221 Ellis SG, Verity MA (1971) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8:212–221
26.
go back to reference Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F et al (2003) Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 61:108–110 Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F et al (2003) Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 61:108–110
27.
go back to reference Karassa FB, Ioannidis JP, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634 Karassa FB, Ioannidis JP, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634
28.
go back to reference Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260 Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260
29.
go back to reference Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA III, Koffler D (1983) Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 74:837–844 Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA III, Koffler D (1983) Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 74:837–844
30.
go back to reference McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet’s disease involving the nervous system. J Neurol Neurosurg Psychiatry 58:548–554 McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet’s disease involving the nervous system. J Neurol Neurosurg Psychiatry 58:548–554
31.
go back to reference Pradhan VD, Badakere SS, Bichile LS, Dolas MP (2002) Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders. J Assoc Physicians India 50:762–765 Pradhan VD, Badakere SS, Bichile LS, Dolas MP (2002) Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders. J Assoc Physicians India 50:762–765
32.
go back to reference Hirohata S, Hayakawa K (1999) Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2729–2730 Hirohata S, Hayakawa K (1999) Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2729–2730
33.
go back to reference Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T (1992) Interferon-alpha in lupus psychosis. Arthritis Rheum 35:417–422 Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T (1992) Interferon-alpha in lupus psychosis. Arthritis Rheum 35:417–422
34.
go back to reference El-Zorkany BK, Mahmoud GA, Shahin HA, Moustafa H, Shahin AA (2003) Tumor necrosis factor-alpha and neuropsychiatric lupus erythematosus: relation to single photon emission computed tomography findings. Mod Rheumatol 13:250–255 El-Zorkany BK, Mahmoud GA, Shahin HA, Moustafa H, Shahin AA (2003) Tumor necrosis factor-alpha and neuropsychiatric lupus erythematosus: relation to single photon emission computed tomography findings. Mod Rheumatol 13:250–255
Metadata
Title
Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus
Authors
Yasuhiro Shimojima
Masayuki Matsuda
Takahisa Gono
Wataru Ishii
Shu-ichi Ikeda
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1060-y

Other articles of this Issue 5/2005

Clinical Rheumatology 5/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.